ClinicalTrials.gg
AvailableNCT07244289Updated Mar 23, 2026

Managed Access Programs for VAY736, Ianalumab

An expanded access record providing ianalumab in Primary Immune Thrombocytopenia and Sjögren's Syndrome, sponsored by Novartis Pharmaceuticals. Available. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Expanded access

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients · Intermediate-size population
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Other kind
2 of 17
none open now
Registered
12th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is one of 2 of another kind, and was the 12th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab

Read the detailed description
  • CVAY736I12003M - Available - Managed Access Program (MAP) Cohort Treatment Plan CVAY736I12003M to provide access to ianalumab (VAY736) for patients with Primary Immune Thrombocytopenia (ITP)
  • CVAY736A1002M - Available - Managed Access Program (MAP) Cohort Treatment Plan CVAY736A1002M to provide access to ianalumab for adult patients with Sjögren's disease
  • CVAY736A1003I - Available - Managed Access Program (MAP) Individual Patient Request (IPR) Cover Letter CVAY736A1003I to provide access to Ianalumab (VAY736) for Sjögren's Disease
  • CVAY736I12004I - Available - Managed Access Program (MAP) Individual Patient Request (IPR) Cover Letter CVAY736I12004I to provide access to Ianalumab (VAY736) for Primary Immune Thrombocytopenia (ITP) and Evans syndrome
03

Conditions studied

  • Primary Immune Thrombocytopenia
  • Sjögren's Syndrome

Keywords

  • MAP
  • Managed Access Program
  • VAY736
  • ianalumab
  • Primary Immune Thrombocytopenia (ITP)
  • Sjögren's Syndrome (SjD)
  • Expanded Access
  • Early Access
  • Compassionate use
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. An independent request was received from a licensed physician.
  2. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.
  3. The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.
  4. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
  5. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
  6. Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
  7. Managed Access provision is allowed per local laws/regulations.
05

Access details

Study type
Expanded access
Access type
Individual patients · Intermediate-size population

Available treatment

  • Patients receive ianalumab

    Also known as: VAY736

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT07244289
Responsible party
Sponsor
First posted
Nov 24, 2025
Last update
Mar 23, 2026

Study contacts

MAP requests are initiated by a licensed physician. https// www.novart is.com/healthcare-professionals/managed-access-programs
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion